Cellular immune response in rats with 1,2-dimethylhydrazine-induced colon cancer after transplantation of placenta-derived multipotent cells

Home/2016, Vol. 4, No. 1/Cellular immune response in rats with 1,2-dimethylhydrazine-induced colon cancer after transplantation of placenta-derived multipotent cells

Cell and Organ Transplantology. 2016; 4(1):55-60.
DOI: 10.22494/COT.V4I1.7

Cellular immune response in rats with 1,2-dimethylhydrazine-induced colon cancer after transplantation of placenta-derived multipotent cells

Svitina H.1,2, Kalmukova O.1, Shelest D.1, Skachkova O.3, Garmanchuk L.1, Shablii V.2
1Educational and Scientific Centre “Institute of Biology”, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
2Institute of Cell Therapy, Kyiv, Ukraine
3National Cancer Institute, Kyiv, Ukraine

We describe the state of the immune system at the late stage of 1,2-dimethylhydrazine (DMH)-induced colon cancer and after administration of placenta-derived multipotent cells (PDMCs). The spleen and thymus indices did not differ among the groups of intact and DMH-treated rats and were not affected by the administration of placenta-derived multipotent cells following the DMH treatment. Moreover, no difference in spontaneous or stimulated phagocytic activity of peritoneal macrophages was observed between healthy rats or the animals with DMH-induced colon cancer (with or without the administration of PDMCs). However, the proliferation of the T cells in the spleen was lower in rats with colon cancer regardless of the administration of PDMCs. Similarly, no changes were observed in the cell cycle distribution of proliferating spleen cells after stimulation by lipopolysaccharide.
Conclusion. Our data demonstrate the absence of the active reaction by peritoneal macrophages and spleen cells to a colon cancer at mid/late stage. Additionally, the administration of PDMCs does not result in a measurable anti-tumor immune response.

Key words: 1,2dimethylhydrazine, colon cancer, placenta-derived multipotent cells, immune response

Full Text PDF (eng) Full Text PDF (ua)

1. Krzystek-Korpacka M, Diakowska D, Kapturkiewicz B, et al. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 2013; 337(1): 107-14.
2. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006; 12(3): 205-11.
3. Lee WS, Baek JH, You DH, et al. Prognostic value of circulating cytokines for stage III colon cancer. J Surg Res. 2013; 182(1): 49-54.
4. Paludan C, Edinger JW, Harbacheuski R, Murray RA, Hariri RJ. Immunomodulation using placental stem cells. US Patent, no US 20150140044 A1, 2015.
5. Evangelista M, Soncini M, Parolini O. Placenta-derived stem cells: new hope for cell therapy? Cytotechnology. 2008; 58(1): 33-42.
PMid:19002775 PMCid:PMC2593758
6. van der Bij GJ, Bögels M, Oosterling SJ, et al. Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett. 2008; 262(1): 77-86.
7. Kruse J, von Bernstorff W, Evert K, et al. Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis. 2013; 28(10): 1337-49.
8. Olszewski WL, Kubicka U, Tarnowski W, et al. Activation of human peritoneal immune cells in early stages of gastric and colon cancer. Surgery. 2007; 141(2): 212-21.
9. Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006; 34(5): 455-65.
10. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005; 5(8): 606-16.
11. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11): 991-8.
12. Scarpa M, Castagliuolo I, Castoro C, et al. Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol. 2014; 20(22): 6774-85.
PMid:24944468 PMCid:PMC4051917
13. Ugurel S, Uhlig D, Pföhler C, et al. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother. 2004; 53: 551-59.
14. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 1997; 18: 493 97.
15. Yuan W, Zong C, Huang Y, et al. Biological, immunological and regenerative characteristics of placenta-derived mesenchymal stem cell isolated using a time-gradient attachment method. Stem Cell Res. 2012; 9(2): 110-23.
16. Brooke G, Rossetti T, Pelekanos R, et al. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol. 2009; 144(4): 571-9.
17. Oliveira MS, Barreto-Filho JB. Placental-derived stem cells: Culture, differentiation and challenges. World J Stem Cells. 2015; 7(4): 769-75.
PMid:26029347 PMCid:PMC4444616
18. Vellasamy S, Sandrasaigaran P, Vidyadaran S, et al. Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. World J Stem Cells. 2012; 4: 53 61.
PMid:22993662 PMCid:PMC3443712
19. Perše M, Cerar A. Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol. 2011; 2011: 473964.
PMid:21253581 PMCid:PMC3018655
20. Chen JR, Yang ZQ, Hu TJ, et al. Immunomodulatory activity in vitro and in vivo of polysaccharide from Potentilla anserina. Fitoterapia. 2010; 81(8): 1117-24.
21. Fang JJ, Zhu ZY, Dong H, et al. Effect of spleen lymphocytes on the splenomegaly in hepatocellular carcinoma-bearing mice. Biomed Environ Sci. 2014; 27(1): 17-26.
22. Sharp JG, Riches AC, Littlewood V, et al. The incidence, pathology and transplantation of hepatomas in CBA mice. J Pathol. 1976; 119(4): 211-20.
23. Toge T, Kuroi K, Kuninobu H, et al. Role of the spleen in immunosuppression of gastric cancer: predominance of suppressor precursor and suppressor inducer T cells in the recirculating spleen cells. Clin Exp Immunol. 1988; 74(3): 409-12.
PMid:2976622 PMCid:PMC1542017
24. Bilynskiy BT, Volodko NA, Shparyk YaV. Immunologicheskie mekhanizmy estestvennoy protivoopukholevoy rezistentnosti [Immunological mechanisms of natural antitumor resistance]. Kiev: Naukova dumka, 1991. 245 p. [in Russian].
25. Medzhitov R, Dzhanevey Ch. Vrozhdennyy immunitet [Natural immunity]. Kazanskiy med. zhurn. 2005; 3: 161-7 [in Russian].
26. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11): 1423-37. doi: 10.1038/nm.3394
27. Luan X, Li G, Wang G, et al. Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34⁺ cells: a comparison with human bone marrow-derived mesenchymal stem cells. Tissue Cell. 2013; 45(1): 32-8.
28. Liu KJ, Wang CJ, Chang CJ, et al. Surface expression of HLA-G is in;ved in mediating immunomodulatory effects of placenta-derived multipotent cells (PDMCs) towards natural killer lymphocytes. Cell Transplant. 2011; 20(11-12): 1721-30.
29. Li CD, Zhang WY, Li HL, et al. Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res. 2005; 15(7): 539-47.
30. Zhu Y, Yang Y, Zhang Y, et al. Placental mesenchymal stem cells of fetal and maternal origins demonstrate different therapeutic potentials. Stem Cell Res Ther. 2014; 5(2): 48.
PMid:24721710 PMCid:PMC4055134
31. Deryagina VP, Ryzhova NI, Golubeva IS. Phagocyte functional activity and production of nitric oxide compounds in mouse models of tumor xenografts. Vestnik RONTs im. N. N. Blokhina RAMN. 2011; 22(2): 49-57.
32. Kladnytska LV, Nikulina VV, Garmanchuk LV, et al. Influence Allogeneic Mesenchymal Stem Cells on the Tumour Growth Parameters and Metastatic Potential in the Transplantable Carcinoma Lung Lewis. Journal of Animal and Veterinary Sciences. 2014; 1(1): 1-5.
33. Kladnytska LV, Mazurkevych AY, Garmanchuk LV, et al. The biological properties of tumor cells in c57bl/6 mice with transplantable lewis lung carcinoma with influence of allogeneic mesenchymal stem cells. The Animal Biology. 2015; 17(2): 82-8.
34. Fang JJ, Zhu ZY, Dong H, et al. Effect of spleen lymphocytes on the splenomegaly in hepatocellular carcinoma-bearing mice. Biomed Environ Sci. 2014; 27(1): 17-26.

Svitina H, Kalmukova O, Shelest D, Skachkova O, Garmanchuk L, Shablii V.  Cellular immune response in rats with 1,2-dimethylhydrazine-induced colon cancer after transplantation of placenta-derived multipotent cells. Cell and Organ Transplantology. 2016; 4(1):55-60. doi: 10.22494/COT.V4I1.7


Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.